Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.

EP: 1.Overview of Atopic Dermatitis Pathophysiology and Atopic March in Children

EP: 2.Considerations for Diagnosing Atopic Dermatitis and Assessing Severity

EP: 3.Exploring the Pediatric Patient and Caregiver Journey

EP: 4.Multidisciplinary Approaches to Atopic Dermatitis Management and Referrals

EP: 5.Setting Goals for Pediatric Atopic Dermatitis Treatment

Now Viewing

EP: 6.Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

Video content above is prompted by the following:

1. 2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
a. Discuss the treatment options with strong recommendations and high certainty of evidence.
i. Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
ii. JAK inhibitors: abrocitinib, baricitinib, upadacitinib